Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)

This publication has 22 references indexed in Scilit:

• Cost analysis of switching from IV vancomycin to PO linezolid for the management of methicillin-resistant Staphylococcus species
  Clinical Therapeutics, 2003
• Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteremia
  Clinical Infectious Diseases, 2003
• Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial
  Surgical Infections, 2003
• Efficacy and Safety of Linezolid in the Treatment of Skin and Soft Tissue Infections
  European Journal of Clinical Microbiology & Infectious Diseases, 2002
• Linezolid versus Vancomycin for the Treatment of Methicillin‐ResistantStaphylococcus aureusInfections
  Clinical Infectious Diseases, 2002
• Clinical Trial Results with Linezolid, an Oxazolidinone, in the Treatment of Soft Tissue and Postoperative Gram-Positive Infections
  Surgical Infections, 2001
• Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
  Diagnostic Microbiology and Infectious Disease, 1999
• The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals
  Emerging Infectious Diseases, 1999
• Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics
  The American Journal of Medicine, 1991
• Economic impact of oral ciprofloxacin following standard intravenous therapy
  Diagnostic Microbiology and Infectious Disease, 1990